Refractory Multiple Myeloma market (2025-2030)
The Refractory Multiple Myeloma market focuses on the treatment of multiple myeloma (MM) cases that do not respond to standard therapies or relapse after initial treatment. Multiple myeloma is a cancer of the plasma cells, and the refractory form signifies resistance to conventional therapies such as chemotherapy and immunomodulatory agents. This market includes novel therapies targeting various aspects of the disease pathophysiology, including immune modulation, proteasome inhibition, and monoclonal antibody therapies.
Disruptive Impact and Opportunities:
The refractory multiple myeloma market is witnessing a paradigm shift driven by the development of novel, targeted therapies that offer hope for patients who have exhausted conventional treatment options. These treatments have the potential to redefine care by providing more effective solutions for patients with relapsed or refractory disease, offering improved survival outcomes, and reducing side effects. New immunotherapy approaches, including bispecific antibodies and CAR-T cell therapies, present a major opportunity for healthcare providers to offer safer, more targeted treatments with fewer adverse effects. As patients and clinicians demand more personalized, efficient, and cost-effective therapies, the market is set to experience a surge in innovation, creating a wealth of opportunities for companies that can deliver these advancements.
Emerging Drugs:
- NEXI 002
- AMG-701
- ABBV 453
Marketed Drugs:
- Bortezomib
- Carfilzomib (Kyprolis)
- Ixazomib (Ninlaro)
Key Companies:
- NexImmune
- Amgen
- AbbVie
- Allogene Therapeutics
- Precision Biosciences
- Takeda Oncology
- ORIC Pharmaceuticals
- Ionis Pharmaceuticals
- Cellectis S.A.
- YZY Biopharma
- Janssen Research & Development
- Bristol Myers Squibb
- Lava Therapeutics
- Prelude Therapeutics
Market Segmentation:
By Type of Treatment:
- Proteasome Inhibitors
- Bortezomib (Velcade)
- Carfilzomib (Kyprolis)
- Ixazomib (Ninlaro)
- Immunomodulatory Drugs (IMiDs)
- Lenalidomide (Revlimid)
- Pomalidomide (Pomalyst)
- Monoclonal Antibodies
- Daratumumab (Darzalex)
- Elotuzumab (Empliciti)
- Isatuximab (Sarclisa)
- Immunotherapies and Cell-based Therapies
- CAR-T Cell Therapy
- Abecma (ide-cel)
- Carvykti (ciltacabtagene autoleucel)
- Bispecific T-cell Engagers
- AMG 701
- BCMA/CD3-targeted therapies
- Other Targeted Therapies
- Venetoclax (Venclexta)
- Selinexor (Xpovio)
- Melflufen (Pepaxto)
By Administration Type:
- Oral Administration
- Lenalidomide (Revlimid)
- Pomalidomide (Pomalyst)
- Ixazomib (Ninlaro)
- Venetoclax (Venclexta)
- Selinexor (Xpovio)
- Intravenous Administration
- Bortezomib (Velcade)
- Carfilzomib (Kyprolis)
- Daratumumab (Darzalex)
- Isatuximab (Sarclisa)
- Abecma (ide-cel)
- Carvykti (ciltacabtagene autoleucel)
What’s in It for You?
- Uncover the latest trends and advancements in refractory multiple myeloma treatment
- Identify key emerging therapies poised to disrupt the market
- Gain insights into leading companies and their market strategies
- Assess the growth potential of the refractory multiple myeloma segment and key therapeutic areas
- Understand how new innovations could redefine patient care and treatment paradigms
